Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 287

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer

Open access
Tarazona, N., Gimeno-Valiente, F., Gambardella, V., Zuñiga, S., Rentero-Garrido, P., Huerta, M., Roselló, S., Martinez-Ciarpaglini, C., Carbonell-Asins, J.A., Carrasco, F., Ferrer-Martínez, A., Bruixola, G., Fleitas, T., Martín, J., Tébar-Martínez, R., Moro, D., Castillo, J., Espí, A., Roda, D., Cervantes, A. · 2019 · Annals of Oncology

Abstract

BACKGROUND: A high percentage of patients diagnosed with localized colon cancer (CC) will relapse after curative treatment. Although pathological staging currently guides our treatment decisions, there are no biomarkers determining minimal residual disease (MRD) and patients are at risk of being undertreated or even overtreated with chemotherapy in this setting. Circulating-tumor DNA (ctDNA) can to be a useful tool to better detect risk of relapse. PATIENTS AND METHODS: One hundred and fifty patients diagnosed with localized CC were prospectively enrolled in our study. Tumor tissue from those patients was sequenced by a custom-targeted next-generation sequencing (NGS) panel to characterize somatic mutations. A minimum variant allele frequency (VAF) of 5% was applied for variant filtering. Orthogonal droplet digital PCR (ddPCR) validation was carried out. We selected known variants with higher VAF to track ctDNA in the plasma samples by ddPCR. RESULTS: NGS found known pathological mutations in 132 (88%) primary tumors. ddPCR showed high concordance with NGS (r = 0.77) for VAF in primary tumors. Detection of ctDNA after surgery and in serial plasma samples during follow-up were associated with poorer disease-free survival (DFS) [hazard ratio (HR), 17.56; log-rank P = 0.0014 and HR, 11.33; log-rank P = 0.0001, respectively]. Tracking at least two variants in plasma increased the ability to identify MRD to 87.5%. ctDNA was the only significantly independent predictor of DFS in multivariable analysis. In patients treated with adjuvant chemotherapy, presence of ctDNA after therapy was associated with early relapse (HR 10.02; log-rank P < 0.0001). Detection of ctDNA at follow-up preceded radiological recurrence with a median lead time of 11.5 months. CONCLUSIONS: Plasma postoperative ctDNA detected MRD and identified patients at high risk of relapse in localized CC. Mutation tracking with more than one variant in serial plasma samples improved our accuracy in predicting MRD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz390

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 287

Metadata

Authors
Tarazona, N., Gimeno-Valiente, F., Gambardella, V., Zuñiga, S., Rentero-Garrido, P., Huerta, M., Roselló, S., Martinez-Ciarpaglini, C., Carbonell-Asins, J. A., Carrasco, F., Ferrer-Martínez, A., Bruixola, G., Fleitas, T., Martín, J., Tébar-Martínez, R., Moro, D., Castillo, J., Espí, A., Roda, D., & Cervantes, A.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-11
Volume
30
Issue
11
Pages
1804-1812
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2976188024
Cited by
287
References
19
FWCI
7.19
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. https://app.cochat.ai/papers/10.1093/annonc/mdz390
The paper
Tarazona, N., Gimeno-Valiente, F., Gambardella, V., Zuñiga, S., Rentero-Garrido, P., Huerta, M., Roselló, S., Martinez-Ciarpaglini, C., Carbonell-Asins, J. A., Carrasco, F., Ferrer-Martínez, A., Bruixola, G., Fleitas, T., Martín, J., Tébar-Martínez, R., Moro, D., Castillo, J., Espí, A., Roda, D., & Cervantes, A. (2019). Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdz390

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.